Journal List > Acute Crit Care > v.38(2) > 1516083680

TOOLS
Choi, Jung, Kim, and Kim: Corrigendum to “Methylprednisolone pulse therapy for critically ill patients with COVID-19: a cohort study”
Corrigendum
Infection

Acute Crit Care 2023;38(2):249-249.

Published online: 25 May 2023

DOI: https://doi.org/10.4266/acc.2022.00941.e1

Corrigendum to “Methylprednisolone pulse therapy for critically ill patients with COVID-19: a cohort study”

Keum-Ju Choi, Soo Kyun Jung, Kyung Chan Kim, Eun Jin Kim

Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu, Korea

Corresponding author Eun Jin Kim Department of Internal Medicine, Daegu Catholic University Medical Center, 33 Duryugongwon-ro 17-gil, Nam-gu, Daegu 42472, Korea Tel: +82-53-650-4274 Fax: +82-53-650-4942 Email: ejkim77@cu.ac.kr

Copyright © 2023 The Korean Society of Critical Care Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Acute and Critical Care 2023;38:57-67
In the article entitled “Methylprednisolone pulse therapy for critically ill patients with COVID-19: a cohort study,” some data of Table 3 was incorrectly presented. The correct Table 3 is as follows.

Table 3.
Treatment and prognosis in critical or severe COVID-19 cases with control and pulse steroid groups
Variable Control steroid (n=14) Pulse steroid (n=30) Total (n=44) P-value
High flow nasal cannula oxygen 14 (100) 29 (96.7) 43 (97.7) 0.490
Mechanical ventilation 4 (28.6) 6 (20.0) 10 (22.7) 0.527
 Duration of mechanical ventilation (day) 18 (11–33) 8 (4–10) 10 (6–8) 0.063
Other treatmenta) 1 (7.1) 3 (10.0) 4 (9.1) 0.759
Prone positionb) 7 (50.0) 21 (70.0) 28 (63.6) 0.199
In-hospital mortality 6 (42.9) 7 (23.3) 13 (29.5) 0.186
In-hospital mortality among moderate and mild ARDS groups 4 (44.4) 2 (13.3) 6 (25.0) 0.088
In-hospital mortality among severe ARDS group 2 (40.0) 5 (33.3) 7 (35.0) 0.933
28-Day mortality 5 (35.7) 7 (23.3) 12 (27.3) 0.390
Cause of death 0.255
 Respiratory failure 4 (28.6) 5 (16.7) 9 (20.5)
 Hepatic failure 2 (14.3) 0 2 (4.5)
 Arrhythmia 0 1 (3.3) 1 (2.3)
 Renal failure 0 1 (3.3) 1 (2.3)
Length of hospital stay (day) 14 (12–24) 11 (9–16) 11 (8–17) 0.039d)
Complication after steroid use 1 (7.1) 3 (9.9) 4 (9.0) 0.295
 Uncontrolled hyperglycemia 0 2 (6.7) 2 (4.8)
 Othersc) 1 (7.1) 1 (3.3) 2 (4.8)

Values are presented as number (%) or median (interquartile range).

COVID-19: coronavirus disease 2019; ARDS: acute respiratory distress syndrome.

a) Other treatment includes renal replacement therapy or extracorporeal membrane oxygenation;

b) Awake prone positioning;

c) One gastrointestinal bleeding case in control steroid group and 1 candidemia case in pulse steroid group;

d) Mann-Whitney U-test for comparisons between the control and pulse steroid groups.

TOOLS
Similar articles